Advertisement

Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 600x60px
Document › Details

PerkinElmer, Inc.. (5/1/17). "Press Release: PerkinElmer Completes Sale of Medical Imaging Business to Varex Imaging". Waltham, MA.

Organisations Organisation PerkinElmer Inc. (NYSE: PKI)
  Group PerkinElmer (Group)
  Organisation 2 Varex Imaging Corporation (Nasdaq: VREX)
  Group Varex Imaging (Group)
Products Product imaging technology (diagnostics)
  Product 2 analytical instrument
Index term Index term PerkinElmer–Varex Imaging: investment, 201612–201705 acquisition $276m cash of PE’s medical imaging business by Varex Imaging (Varian Medical Systems)
Person Person Friel, Robert F. (PerkinElmer 200802– CEO before COO before President Life+Analytical joined 1999 as CFO)
     


PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the company has completed the sale of its Medical Imaging business to Varex Imaging Corporation (Nasdaq: VREX).

PerkinElmer announced its intent to sell its Medical Imaging business, a supplier of flat panel X-ray detectors that serve as components for industrial, medical and dental X-ray imaging systems, on December 22, 2016.

"The sale of Medical Imaging supports our strategy of redirecting our investments towards accelerating growth in key markets," said Robert Friel, Chairman and Chief Executive Officer, PerkinElmer.


About PerkinElmer

PerkinElmer, Inc. is a global leader focused on innovating for a healthier world. The Company reported revenue of approximately $2.1 billion in 2016, has about 9,000 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.


Factors Affecting Future Performance

This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities and divestitures. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products declining or not growing as anticipated; (2) fluctuations in the global economic and political environments; (3) our failure to introduce new products in a timely manner; (4) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable, or successfully divest businesses; (5) our failure to adequately protect our intellectual property; (6) the loss of any of our licenses or licensed rights; (7) our ability to compete effectively; (8) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (9) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (10) disruptions in the supply of raw materials and supplies; (11) the manufacture and sale of products exposing us to product liability claims; (12) our failure to maintain compliance with applicable government regulations; (13) regulatory changes; (14) our failure to comply with healthcare industry regulations; (15) economic, political and other risks associated with foreign operations; (16) our ability to retain key personnel; (17) significant disruption in our information technology systems; (18) our ability to obtain future financing; (19) restrictions in our credit agreements; (20) the approval of the Brexit Referendum in the United Kingdom; (21) our ability to realize the full value of our intangible assets; (22) significant fluctuations in our stock price; (23) reduction or elimination of dividends on our common stock; and (24) other factors which we describe under the caption "Risk Factors" in our most recent annual report on Form 10-K and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170501006261/en/

PerkinElmer, Inc.
Investor Relations:
Tommy J. Thomas, 781-663-5889
tommy.thomas@perkinelmer.com
or
Media:
Brian Willinsky, 781-663-5728
brian.willinsky@perkinelmer.com


   
Record changed: 2017-05-03

Advertisement

Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 600x60px

More documents for PerkinElmer (Group)


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

Picture Eurasanté BioFIT 2017 Strasbourg France November 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px